Position in GENB
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$32,802,466
+$8,497,141 QoQ
Shares Held
1,944,426
0.0% QoQ
Ownership
1.51%
of shares outstanding
% of Portfolio
2.98%
of 13F equity value
Holder Rank
#7
of 85 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GENB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARCH Venture Management, LLC holds $1,092,140,745 across 11 Biotechnology names. GENB ranks #9 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PBLS |
Parabilis Medicines, Inc.
|
6,412,780 | $175,517,788 | |
| 2 | BEAM |
Beam Therapeutics Inc.
|
4,540,132 | $155,817,330 | |
| 3 | RAPP |
Rapport Therapeutics, Inc.
|
3,728,738 | $155,376,512 | |
| 4 | SPTX |
Seaport Therapeutics, Inc.
|
6,294,951 | $136,726,335 | |
| 5 | ERAS |
Erasca, Inc.
|
7,091,557 | $129,917,324 | |
| 6 | VIR |
Vir Biotechnology, Inc.
|
12,694,163 | $129,353,520 | |
| 7 | MAZE |
Maze Therapeutics, Inc.
|
4,120,053 | $122,942,381 | |
| 8 | LYEL |
Lyell Immunopharma, Inc.
|
3,247,162 | $45,622,626 |
All Filings in GENB
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $32,802,466 | 1,944,426 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $24,305,325 | 1,944,426 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||